Skip to content
Monday, November 16, 2026
Bold Betting World

Users Coming Off Anti-Obesity Jabs Regain Pounds at a Quadrupled Rate Than Dieters

Image of medical injection and scale
Obesity treatment often requires long-term strategies.

Fresh analysis suggests that patients who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise regimens.

Research printed in a prominent medical journal points out that while overweight individuals can lose substantial amounts of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month once they quit.

"Users buying these treatments should be aware of the risk of fast weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.

Such speed of regain means a return to pre-treatment weight within about a year and a half.

Comparing Treatments

The research, which reviewed dozens of studies involving thousands of participants, compared the outcomes of the injectable medications with other pills.

Researchers emphasize that people who lose weight through lifestyle changes alone usually experience a more gradual weight regain—approximately 0.1 kg a month—post-intervention.

The Reason for the Quick Rebound

Doctors believe the mode of action of the jabs accounts for the heightened regain.

These medications imitate a natural hormone called GLP-1, which controls feelings of fullness.

"Sustained high doses of the hormone concentrations several times higher than the body's typical production could lead to the body to produce less of its own natural hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.

"Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating far more likely."

An Ongoing Condition?

The NHS suggest the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.

A number of clinicians argue that, considering the likelihood of relapse, the therapy might need to be long-term.

This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.

Patient Accounts

Users who have come off the jabs report a powerful return of appetite.

"I experienced a switch flipping and you become starving," said one woman.

The struggle is exacerbated if individuals have not developed sustainable lifestyle or habit changes during treatment.

Significant Adoption

Survey data suggest that millions of adults in the UK have tried these injections in the past year, with interest being substantial.

  • Use is more common among females compared to males.
  • The middle-aged demographic shows the greatest level of interest.
  • Many access the drugs through private healthcare rather than the NHS.

Finally, researchers emphasize that while these medications are powerful agents for shedding pounds, they are not a magic fix and long-term success hinges on integrated lifestyle management.

Written by

Courtney Mullins

A former professional sports analyst turned betting strategist, specializing in data-driven predictions and risk management techniques.

Bold Betting World

Type to search articles.